Development of novel radioligand for PET imaging targeting the orexin 1 receptor

NIH RePORTER · NIH · R03 · $193,923 · view on reporter.nih.gov ↗

Abstract

Project Summary (Abstract) Addiction is a chronic relapsing disorder characterized by compulsive drug-seeking which persists despite adverse consequences [WHO 1992; American Psychiatric Association 2013]. in the past few years, misuse of opioids (both prescribed and illegal) increased considerably. However, there are very few effective and approved pharmacotherapies available [Pierce et al. 2012]. Recent research activities in the field of orexin biology have demonstrated the significance of these receptors in the domain of addiction. The development of a PET imaging tracer would permit detection and quantification of orexin receptors in vivo thereby accelerating research and increasing our understanding of orexin functions in the domain of drug addiction. The specific aims of this project, will focus on the synthesis, evaluation and characterization of potential OX1R antagonists (Aim 1). Perform In vivo quantification of the binding potential (BP) of the candidate OX1R radiotracer in baboons (Aim 2). If successful, this project will provide “proof of concept” imaging data and a lead PET imaging tracer that can be further examined in human as part of a future R01 application.

Key facts

NIH application ID
10784351
Project number
1R03DA059714-01
Recipient
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Principal Investigator
Isabelle Kovacic
Activity code
R03
Funding institute
NIH
Fiscal year
2024
Award amount
$193,923
Award type
1
Project period
2024-04-01 → 2027-03-31